Spruce Biosciences/SPRB

$5.02

-6.86%
-
1D1W1MYTD1YMAX

About Spruce Biosciences

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). The Company is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS) with adrenal dysfunction. The Company has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with highly elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction.

Ticker

SPRB

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Grey

Employees

31

Headquarters

South san francisco, United States

SPRB Metrics

BasicAdvanced
$223.5M
Market cap
-
P/E ratio
-$1.49
EPS
2.73
Beta
-
Dividend rate

What the Analysts think about SPRB

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 7 analysts.
73.51% upside
High $10.00
Low $7.00
$5.02
Current price
$8.71
Average price target

SPRB Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-410% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$3M
42.86%
Net income
$-12.3M
-3.91%
Profit margin
-410%
-32.73%

SPRB Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.09%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.47
-$0.40
-$0.32
-$0.30
-
Expected
-$0.53
-$0.36
-$0.39
-$0.35
-$0.39
Surprise
-11.32%
10.42%
-18.44%
-15.09%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Spruce Biosciences stock

Buy or sell Spruce Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing